Genetic risk and atrial fibrillation in patients with heart failure

Mariëlle Kloosterman1†, Bernadet T. Santema1‡, Carolina Roselli1,2, Christopher P. Nelson3, Andrea Koekemoer3, Simon. P.R. Romaine3, Isabelle C. Van Gelder1, Carolyn S.P. Lam1,4, Vicente A. Artola1, Chim C. Lang5, Leon L. Ng3, Marco Metra6, Stefan Anker7, Gerasimos Filippatos8, Kenneth Dickstein9, Piotr Ponikowski10, Pim van der Harst1, Peter van der Meer1, Dirk J. van Veldhuijen1, Emelia J. Benjamin11, Adriaan A. Voors1, Nilesh J. Samani3, and Michiel Rienstra1*.

1Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; 2Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, MA, USA; 3Department of Cardiovascular Sciences, University of Leicester and NIHR Leicester Biomedical Research Centre, Leicester, UK; 4National Heart Centre, Singapore, Singapore; 5School of Medicine Centre for Cardiovascular and Lung Biology, Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK; 6Institute of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy; 7Department of Cardiology (CVK), Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany; 8Athens University Hospital, Athens, Greece; 9University of Bergen, Stavanger University Hospital, Bergen, Norway; 10Department for Heart Disease, Centre for Heart Disease, University Hospital, Medical University, Wroclaw, Poland; and 11Department of Medicine, Boston University School of Medicine, Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.

Received 30 September 2019; revised 28 September 2019; accepted 29 November 2019.

Aims To study the association between an atrial fibrillation (AF) genetic risk score with prevalent AF and all-cause mortality in patients with heart failure.

Methods and results An AF genetic risk score was calculated in 3759 European ancestry individuals (1783 with sinus rhythm, 1976 with AF) from the BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF) by summing 97 single nucleotide polymorphism (SNP) alleles (ranging from 0–2) weighted by the natural logarithm of the relative SNP risk from the latest AF genome-wide association study. Further, we assessed AF risk variance explained by additive SNP variation, and performance of clinical or genetic risk factors, and the combination in classifying AF prevalence. AF was classified as AF or atrial flutter (AFL) at baseline electrocardiogram and/or a history of AF or AFL. The genetic risk score was associated with AF after multivariable adjustment. Odds ratio for AF prevalence per 1-unit increase genetic risk score was 2.12 (95% confidence interval 1.84–2.45, $P = 2.15 \times 10^{-24}$) in the total cohort, 2.08 (1.72–2.50, $P = 1.30 \times 10^{-14}$) in heart failure with reduced ejection fraction (HFrEF) and 2.02 (1.37–2.99, $P = 4.37 \times 10^{-6}$) in heart failure with preserved ejection fraction (HFpEF). AF-associated loci explained 22.9% of overall AF SNP heritability. Addition of the genetic risk score to clinical risk factors increased the C-index by 2.2% to 0.721.

Conclusions The AF genetic risk score was associated with increased AF prevalence in HFrEF and HFpEF. Genetic variation accounted for 22.9% of overall AF SNP heritability. Addition of genetic risk to clinical risk improved model performance in classifying AF prevalence.

Keywords Atrial fibrillation • Heart failure • Genetic association studies • Single nucleotide polymorphism • Risk factors

*Corresponding author. Department of Cardiology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands. Tel: +31 50 3611327. Fax +31 50 3614391. Email: m.rienstra@umcg.nl
†These authors are joint first authors.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Introduction

Atrial fibrillation (AF) is the most common cardiac arrhythmia and is highly prevalent in patients with heart failure.\(^1\)\(^-\)\(^3\) The co-existence of these conditions can be expected by virtue of their prevalence alone: the lifetime risk of developing AF is about one in three in individuals of European ancestry and one in five in individuals of African ancestry,\(^4\)\(^-\)\(^6\) and after age 45 the lifetime risk of heart failure ranges between 20–45%.\(^7\)

Furthermore, both conditions have many shared risk factors which makes their co-existence more likely.\(^8\)\(^-\)\(^9\) Additionally, a reciprocal relation between both conditions seems to exist, but regardless of which condition occurs first, the concomitant presence of both AF and heart failure is associated with substantially increased risks of mortality.\(^2\)\(^-\)\(^3\)

Atrial fibrillation is common in heart failure and prevalence of the arrhythmia increases with heart failure severity, but little is known about the mechanisms that underlie AF onset in heart failure patients.\(^10\)\(^-\)\(^11\) Genetic factors could theoretically explain, at least partly, the increased risk of AF in patients with heart failure.\(^12\) But heritability of AF is complex; in a recent study, 97 genome-wide susceptibility loci for AF were identified, and the proportion of heritability explained by the loci in individuals of European ancestry was 42%.\(^13\) Prevalence estimates of heart failure in population-based biobanks and case-referent studies used for AF genome-wide association studies (GWAS) is limited, and it remains unclear whether individuals with AF in the context of heart failure share a similar genetic susceptibility to the arrhythmia.

We aimed to study the association between a genetic risk score based on 97 lead single nucleotide polymorphisms (SNPs)\(^13\) with prevalent AF and all-cause mortality in a large sample of patients with heart failure included in The BIOlogy Study to TAilored Treatment in Chronic Heart Failure (BIOSTAT-CHF). Further, we assessed the variance in AF prevalence explained by additive SNP variation (SNP heritability), and determined the discriminatory accuracy of clinical risk factors, genetic risk factors, and the combination in classifying AF prevalence.

Methods

Study population

The prospective, observational, international BIOSTAT-CHF study included 2516 patients with heart failure from 11 European countries between December 2010 and December 2012. Another 1738 patients from Scotland were included in a validation cohort between October 2010 and April 2014. The rationale, design, and primary results have been previously published.\(^14\) Briefly, the majority of patients were hospitalized for acute heart failure, and the remainder presented with worsening signs and/or symptoms of heart failure at outpatient clinics. Patients had to have objective evidence of cardiac dysfunction documented either by left ventricular ejection fraction (LVEF) of ≤40%, previous heart failure hospitalization, or plasma concentrations of B-type natriuretic peptide (BNP) and/or N-terminal pro-B-type natriuretic peptide (NT-proBNP) >400 pg/mL or >2000 pg/mL, respectively. According to study design, all patients used diuretics but were not on optimal, evidence-based medical therapy of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and/or beta-blockers. After inclusion patients were extensively phenotyped and genotyped, underwent physical examination and quality of life measurements, and plasma, serum, and urine samples were collected for analysis. During the first 3 months of follow-up, medication was optimized. The study complies with the Declaration of Helsinki, medical ethics committee of participating centres approved the study, and all patients provided written informed consent before inclusion.

Patient selection

For the current analysis the BIOSTAT-CHF index cohort (\(n = 2516\)) and validation cohort (\(n = 1738\)) were combined to achieve a larger set of patients (\(n = 4254\)). Patients with no blood samples available for genotyping (\(n = 166\)), self-reported non-European ancestry (\(n = 37\)), and pacemaker rhythm or missing variables that prohibited rhythm classification (\(n = 292\)) were excluded (Figure 1).

Figure 1 Flowchart of the final BIOSTAT-CHF study population. AF, atrial fibrillation; ECG, electrocardiogram; HfPvEF, heart failure with preserved ejection fraction; HfPEF, heart failure with reduced ejection fraction; PM, pacemaker; SNP, single nucleotide polymorphism; SR, sinus rhythm.

Atrial fibrillation prevalence and all-cause mortality

Atrial fibrillation prevalence was defined as clinical history of AF or atrial flutter (AFL) and/or AF(L) on baseline electrocardiogram (ECG). Patients were regarded as having sinus rhythm if they had no history of AF and sinus rhythm on baseline ECG. Incident AF was not captured during follow-up.

After the optimization (3 months) and maintenance phase (6 months),\(^14\) patients were followed by standard clinical follow-up or telephone contact with 6-month intervals. Follow-up ended on April 1st 2015. Median follow-up duration was approximately

© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Genotyping in BIOSTAT-CHF

The two cohorts were processed, genotyped, QC’d and imputed independently, using the same protocols. Genotyping of all patients from both BIOSTAT-CHF cohorts was performed using the Affymetrix Axiom Genome-Wide UKB WCGS genotyping array. Sample level QC was performed for X chromosome homozygosity (sex mismatch) and identity by descent (IBD) estimates (relatedness and duplicates). Prior to imputation, variants were removed if their call rate was <95% for variants with minor allele frequency (MAF) ≥5%, or <99% for variants with MAF <5%, or if any patients had Hardy–Weinberg equilibrium P < 1x10⁻⁶. Imputation was performed using SHAPEIT²¹ and IMPUTE²² with the phase 3 release 1000G reference panel.¹⁷

Genetic analysis

Atrial fibrillation genetic risk score

Genotypes of 97 SNPs associated with AF risk in the latest published GWAS were calculated using PLINK v2.00.¹⁸ The SNP rs465276 was not available in BIOSTAT-CHF and was substituted with a proxy (rs361834, r² = 0.91, based on pairwise linkage disequilibrium from European ancestry samples in the Broad AF study).⁸ All SNPs had an INFO score >0.4 and a Hardy–Weinberg equilibrium P > 1x10⁻⁶. AF genetic risk scores were calculated using PLINK v2.00.¹⁸

Proportion of heritability explained

We assessed the proportion of AF phenotypic variance explained by additive genetic variation, otherwise referred to as SNP heritability (h²). h² was calculated with the software BOLT-LMM v2.3.2.¹⁹ The AF loci were defined as a region of 1 Mb (±500 kb) around each of the 97 reported sentinel variants from the latest AF GWAS (online supplementary Table S1). The SNP rs465276 was not available in BIOSTAT-CHF and was substituted with a proxy (rs361834, r² = 0.91, based on pairwise linkage disequilibrium from European ancestry samples in the Broad AF study).⁸ All SNPs had an INFO score >0.4 and a Hardy–Weinberg equilibrium P > 1x10⁻⁶. AF genetic risk scores were calculated using PLINK v2.00.¹⁸

Statistical analyses

Normally distributed variables are depicted as means ± standard deviation and non-normally distributed variables as median with the first and third quartile (Q1, Q3). Categorical variables are presented as numbers with percentages. Multivariable logistic regression models were used to examine whether a genetic risk score build of 97 AF genetic loci was associated with AF prevalence. Model 1 was adjusted for age, sex, and the first 10 principal components of ancestry. Model 2 was adjusted for clinical AF risk factors from the CHARGE-AF risk model,²² a model aimed to predict future risk of AF. Variables include: age, height, weight, systolic and diastolic blood pressure, current smoking, hypertension as a proxy for antihypertensive treatment, diabetes, myocardial infarction, and the first 10 principal components of ancestry. The CHARGE-AF risk model variables heart failure and race were not included since our population consists of European ancestry patients with heart failure. A total of 96 patients had missing values and were excluded. We calculated the area under the receiver operating curve (AUC) in logistic regression models for AF prevalence. All calculations included the first 10 principal components and were performed in R using the package pROC²³ to calculate the AUC and the 95% confidence intervals (CI) with the DeLong method. Cox proportional hazard analysis was performed to determine hazard ratios (HR) with 95% CI for the genetic risk score and all-cause mortality. All HR were adjusted for covariates of the CHARGE-AF risk model. The Cox proportional hazards assumption was assessed by visually inspecting plots of Schoenfeld residuals against time, which showed no proportionality violation (i.e. the plots showed random patterns of residuals against time). Interaction testing was performed to determine whether the effect of the genetic risk score differed between the heart failure phenotypes, with regard to AF prevalence and all-cause mortality risk. Secondary analyses were performed in subgroups based on LVEF: LVEF <40% and LVEF ≥50%, respectively, heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HfP EF). Patients with a mid-range ejection fraction (LVEF 40–49%) or missing LVEF data were not assessed separately. Analyses were performed using IBM SPSS Statistics version 23. The a priori significance threshold for all analyses was P < 0.05 using 2-sided tests.

Results

Patient characteristics

An overview of the cohort is shown in Table 1. A total of 3759 European ancestry individuals from BIOSTAT-CHF were included, of whom 1976 (53%) had prevalent AF. Mean age was 72.8 ± 11.5, 30% were women. These patients were further stratified in 2262 HFrEF patients, of whom 1137 (50.3%) were in sinus rhythm and 1125 (49.7%) had AF, and 530 HfP EF patients, of whom 223 (42%) were in sinus rhythm and 307 (58%) had AF (Figure 7). Overall, patients with AF were older (75.0 ± 10.2 vs. 70.3 ± 12.3 years), more often men (73% vs. 67%), and had a higher body mass index (28.7 ± 5.9 vs. 28.0 ± 5.9 kg/m²). AF patients more often had renal disease (38% vs. 29%), but less often had coronary artery disease (43% vs. 54%) (all P < 0.001).

Genetic risk score and atrial fibrillation prevalence

In the total cohort, the AF genetic risk score ranged between 4.62 to 8.29 with a median of 6.37. After multivariable adjustment, the odds ratio for AF presence was 2.12 per 1-unit
### Table 1 Baseline characteristics

<table>
<thead>
<tr>
<th>Demographics</th>
<th>Overall (n = 3759)</th>
<th>AF (n = 1976, 53%)</th>
<th>SR (n = 1783, 47%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, years</strong></td>
<td>72.8 ± 11.5</td>
<td>75.0 ± 10.2</td>
<td>70.3 ± 12.3</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Women, n (%)</strong></td>
<td>1128 (30)</td>
<td>537 (27)</td>
<td>591 (33)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>NYHA class I/II/III/IV, %</strong></td>
<td>6/43/36/7</td>
<td>5/46/41/8</td>
<td>8/47/37/8</td>
<td>0.001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical variables</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BMI, kg/m²</strong></td>
<td>28.3 ± 5.9</td>
<td>28.7 ± 5.9</td>
<td>28.0 ± 5.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Blood pressure, mmHg</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>125 ± 22</td>
<td>124 ± 21</td>
<td>127 ± 23</td>
<td>0.002</td>
</tr>
<tr>
<td>Diastolic</td>
<td>73 ± 14</td>
<td>73 ± 14</td>
<td>72 ± 13</td>
<td>0.01</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>78 ± 19</td>
<td>80 ± 21</td>
<td>75 ± 16</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medical history, n (%)</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Coronary artery disease⁴</td>
<td>1814 (48)</td>
<td>856 (43)</td>
<td>958 (54)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hypertension</td>
<td>2295 (61)</td>
<td>1221 (62)</td>
<td>1074 (60)</td>
<td>0.32</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>1218 (32)</td>
<td>657 (33)</td>
<td>561 (31)</td>
<td>0.25</td>
</tr>
<tr>
<td>Renal disease⁴</td>
<td>1276 (34)</td>
<td>757 (38)</td>
<td>519 (29)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Echocardiographic data</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>LVEF, %</td>
<td>35 ± 13</td>
<td>36 ± 13</td>
<td>34 ± 13</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HFrEF⁵, n (%)</td>
<td>2262 (60)</td>
<td>1125 (57)</td>
<td>1137 (64)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>HFP EF³, n (%)</td>
<td>530 (14)</td>
<td>307 (16)</td>
<td>223 (13)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Laboratory data</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>NT-proBNP, ng/L, median (IQR)</td>
<td>2096 (825–4861)</td>
<td>2537 (1128–5122)</td>
<td>1588 (515–4510)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Medications, n (%)</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ACEi/ARB</td>
<td>2681 (71)</td>
<td>1370 (69)</td>
<td>1311 (74)</td>
<td>0.005</td>
</tr>
<tr>
<td>Beta-blocker</td>
<td>2410 (64)</td>
<td>1307 (66)</td>
<td>1103 (62)</td>
<td>0.18</td>
</tr>
<tr>
<td>MRA</td>
<td>1670 (44)</td>
<td>872 (44)</td>
<td>798 (45)</td>
<td>0.37</td>
</tr>
<tr>
<td>Diuretics</td>
<td>3735 (99)</td>
<td>1960 (99)</td>
<td>1775 (99)</td>
<td>0.01</td>
</tr>
</tbody>
</table>

ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; HFrEF, heart failure with reduced ejection fraction; HFP EF, heart failure with preserved ejection fraction; IQR, interquartile range; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; SR, sinus rhythm.

⁴Coronary artery disease defined as: previous myocardial infarction, percutaneous coronary intervention and/or coronary artery bypass graft. Renal disease defined as estimated glomerular filtration rate < 60 mL/min/1.73 m².

⁵HFrEF defined as LVEF < 40%.

⁶HFP EF defined as LVEF ≥ 50%.

---

**Figure 2** Genetic risk score and risk of atrial fibrillation prevalence. The bars signify the 95% confidence interval, the clear symbols represent results of model 1 and the solid symbols results of model 2. Squares indicate the total cohort, circles patients with heart failure with reduced ejection fraction (HFrEF), and triangles patients with heart failure with preserved ejection fraction (HFP EF). Model 1: adjusted for age, sex, and first 10 principal components of ancestry. Model 2: adjusted for age, height, weight, systolic and diastolic blood pressure, current smoking, hypertension, diabetes, myocardial infarction, and first 10 principal components of ancestry.
Figure 3   Increasing atrial fibrillation (AF) risk according to genetic risk score tertiles in the total cohort. The bars signify the 95% confidence interval, the clear symbols represent results of model 1 and the solid symbols results of model 2. Squares indicate the total cohort. Model 1: adjusted for age, sex, and first 10 principal components of ancestry. Model 2: adjusted for age, height, weight, systolic and diastolic blood pressure, current smoking, hypertension, diabetes, myocardial infarction, and first 10 principal components of ancestry.

Table 2 Proportion of heritability explained by atrial fibrillation loci

<table>
<thead>
<tr>
<th>Study</th>
<th>AF-loci $h^2_g$ observed (SE)</th>
<th>AF-loci $h^2_g$ liability scale (SE)</th>
<th>Remaining genome $h^2_g$ observed (SE)</th>
<th>Remaining genome $h^2_g$ liability scale (SE)</th>
<th>Overall $h^2_g$ liability scale</th>
<th>Proportion explained (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>97 AF loci</td>
<td>0.0557 (0.0297)</td>
<td>0.0876 (0.0468)</td>
<td>0.1873 (0.1135)</td>
<td>0.2947 (0.1786)</td>
<td>0.3823</td>
<td>22.92</td>
</tr>
</tbody>
</table>

AF, atrial fibrillation; $h^2_g$, single nucleotide polymorphism heritability; SE, standard error.

Proportion of AF single nucleotide polymorphism heritability explained by AF loci, defined as a 1 Mb region around sentinel variants.

There was no interaction between genetic risk score and heart failure type on AF prevalence ($P = 0.99$). We estimated odds ratios comparing individuals in genetic risk score tertiles (Figure 3). The odds ratio for AF prevalence increased with higher genetic risk score categories. For the total BIOSTAT-CHF population, those in the highest tertile had 2.23 fold increased risk of AF compared to those in the lowest tertile (95% CI 1.87–2.65, $P = 1.26 \times 10^{-19}$).

Heritability and atrial fibrillation prevalence classification models

Atrial fibrillation-associated loci explain 22.9% of the overall AF SNP heritability ($h^2_g$) in our heart failure sample (Table 2).

The CHARGE-AF risk model had an AUC of 0.699 (95% CI 0.682–0.716) for accurately classifying AF prevalence, and was better than the genetic risk score alone (AUC 0.606; 95% CI 0.588–0.624). Combining the AF genetic risk score with the CHARGE-AF risk variables led to a model with an AUC of 0.721 (95% CI 0.704–0.737), a 2.2% increase over the CHARGE-AF risk model alone (Table 3).

Genetic risk score and all-cause mortality

During follow-up, with a median of 656 days (interquartile range 448–872 days), 1062 patients died (28%). In the total cohort, the genetic risk score was not associated with an increased risk for all-cause mortality after multivariable adjustment (HR 0.93, 95% CI 0.82–1.05, $P = 0.22$). Similar results were observed for the HFrEF (HR 0.92, 95% CI 0.78–1.08, $P = 0.31$) and HfPfEF (HR 1.12, 95% CI 0.85–1.48, $P = 0.44$) subgroups. There was no interaction between heart failure subgroup and the genetic risk score on outcome ($P = 0.63$).
Discussion

In 3759 heart failure patients of European ancestry, an AF genetic risk score, based on lead SNPs at 97 AF loci, was associated with a higher prevalence of AF after adjustment for clinical AF risk variables from the CHARGE-AF risk model. We observed that 22.9% of variance in AF risk was attributable to additive genetic variation. Furthermore, addition of the AF genetic risk score to clinical risk factors improved risk model performance in classifying AF prevalence. The AF genetic risk score was not associated with all-cause mortality. Our findings support and extend the prior observation that there is, at least, a partial genetic basis for AF in patients with HFrEF and HFP EF.12

Atrial fibrillation genetic risk score and all-cause mortality

Previous analyses in BIOSTAT-CHF have shown that worse cardiovascular outcomes were seen in heart failure patients with AF compared to sinus rhythm.24 Nevertheless, after multivariable adjustment, the AF genetic risk score was not associated with all-cause mortality. However, a genetic risk score alone does not capture the clinical significance of AF presence in patients with an extensive cardiac substrate and other underlying risk factors. Additionally, current observations may be affected by survival bias.

Implications

The clinical risk factor model alone outperformed the genetic risk score, this is to be expected since compared to clinical risk factors the effect size of genetic variants is small, even when combined in a polygenic risk score. Although the genetic risk score had moderate discriminatory accuracy, we demonstrated that a combined risk model, consisting of the AF genetic risk score with clinical AF risk factors as present in the CHARGE-AF risk model, performed better than either risk model alone. But statistical significance does not automatically translate into clinical significance, and currently translation of genetics into clinical practice remains unresolved.

In the future, genetic profiling may provide insight into the mechanisms that underlie why some patients develop AF and others do not. The individual SNPs implicate genes that may reveal some of the mechanisms underlying AF (online supplementary Figure S1).13 Currently, most genes represent gene candidates at the loci, while the causal gene remains unknown. Experimental observations illustrate the pleiotropic nature of genes that are associated with this challenging arrhythmia and underscore the complexity of AF; so does PITX2 encodes a transcription factor that plays a role in the formation of the pulmonary vein myocardium.25 does TBX5 encodes transcription factors that are required for patterning and maturing of the cardiac conduction system in mice26 and have KCNN3 and SCN5A, which both encode subunits of the potassium channel complex, been previously been linked to AF through candidate gene analyses and family-based studies.27 More insights into the functional consequences of SNPs and genes is critical to identify potential therapeutic targets for this major health burden.28 However, whether the genetic proportion to AF risk has a meaningful contribution to clinical risk assessment warrants further investigation.

Limitations

Current results, based on genetic data of 97 SNPs in 3759 patients from a well-defined heart failure cohort, point towards a genetic basis for AF in the context of heart failure. Analyses were limited to European ancestry individuals, and the current heart failure sample had a higher percentage of men with only 30% of women, and a higher percentage of HFrEF than is typical in the community; the findings may not be completely generalizable to individuals of different ancestral backgrounds, regions, or the general heart failure population. Additionally, women and men generally have a different

© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.

Genetic basis for atrial fibrillation in heart failure patients

Atrial fibrillation and heart failure frequently co-exist, but direct causality has not been unequivocally proven. Additionally, the underlying mechanisms that lead to the development of AF in HFrEF and HFP EF and vice versa remain complex and not completely understood. Previously the ZFHX3 gene was found to be associated with AF presence in a heart failure population.12 Our comprehensive AF genetic risk score of 97 SNPs, together with the estimation that 22.9% of the phenotypic variance is explained by additive genetic variation, provide evidence of a substantial contribution of genome-wide variation to AF susceptibility in heart failure patients.

The genetic contribution to AF in our heart failure sample is less than what was previously observed in population based- and case-referent AF-GWAS studies, which also included a proportion of patients with heart failure (approximately 23% vs. 42%). Part of this portion of missing heritability may be caused by unidentified common genetic variants. Gene–environment interactions may also play a role, as genetic variants can also have associations with risk factors (pleiotropic effects). Heart failure patients have many risk factors including age, hypertension, diabetes, obesity, as well as valvular, ischaemic and non-ischaemic structural heart disease.10,11 On the other hand, increased cardiac filling pressures and consequently atrial stretch, cardiac fibrosis, dysregulation of intracellular calcium, and autonomic and neuroendocrine dysfunction in the setting of heart failure may evoke AF. It is possible that in the context of heart failure, with several concomitant risk factors, genetics may play a smaller role than in the general population.

It is hypothesized that AF in the presence of HFrEF is a marker of more advanced cardiac disease, with ventricular function deterioration and increased neurohormonal activation, while patients with AF and HFP EF share a more underlying substrate, albeit heterogeneous, with many shared risk factors.10,11 A difference in the genetic contribution to AF in HFrEF or HFP EF is not evident from current results, as no interaction between genetic risk score and heart failure type was observed.
risk factor burden, which next to genetics and the underlying heart failure substrate, may be of different importance in the presence of concomitant heart failure and prevalent AF. Second, the genetic risk models were linear in nature with a single predictor variable and did not account for potential non-additive genetic effects, interactions between genetic variants, or interactions between genetic variants and environmental factors. Therefore, all observations are vulnerable to the risk of residual confounding that may bias mentioned estimates. Thirdly, AF ascertainment was partially based on physician-reported AF. This means that the percentage of AF is likely an underestimation since subclinical AF may have gone undetected. Fourthly, whether heart failure developed before the onset of AF, or AF before the onset of heart failure may be associated with a different genetic risk. Also the sequence in which the diseases develop can impact outcome. Unfortunately, we did not have information on the onset of AF and heart failure; therefore a temporal sequence of diagnoses was unknown, prohibiting time-dependent analyses. AF occurrence during follow-up was not systematically collected and therefore current analyses focus on baseline AF prevalence. Additionally, there was a lack of data on type and duration of AF, as well as applied therapies for AF. Fifthly, electro- and echocardiographic variables such as left atrial volume were omitted from the models since they were not available in a large proportion of patients. Additionally, these biomarkers will be influenced by both the underlying heart failure substrate as well as AF presence, duration, and severity. Covariates including LVEF. New York Heart Association class and NT-proBNP will be confounded by AF itself as it inhibits adequate echocardiographic determination of ejection fraction, is associated with symptoms of dyspnea, and will lead to an increase in NT-proBNP levels. In line with the previous limitation, we did not adjust for heart failure severity in the multivariable models. We acknowledge that the CHARGE-AF model application in heart failure was not ideal, albeit the best validated AF risk score. Sixthly, in determining SNP heritability we assessed variants with MAF ≥1%, and, therefore, the contribution of rare or loss-of-function variants to total AF variance was not assessed. Furthermore, the estimates for SNP heritability have large standard errors bringing a level of uncertainty to these estimates. Seventhly, we cannot attribute the AF risk variance to functional categories. It remains challenging to identify the causal gene at each locus since the AF-associated SNPs predominantly fall within non-coding portions of the genome. Additionally, the association of genes to functional groups is based on their affiliation to enriched gene sets that were identified in an in silico analysis. Lastly, establishing a heart failure cohort of sufficient size is complex, and the current study is underpowered to study individual SNPs or perform extensive subgroup analyses. Larger studies, powered for outcomes, are warranted to investigate the genetic contribution to incident AF in heart failure populations, both HFrEF and HfP EF. Further efforts are needed to uncover the functional consequence of SNPs and genes at each locus on AF risk in patients with incident heart failure.

Conclusion
The AF genetic risk score was associated with increased AF prevalence in heart failure patients with reduced and preserved ejection fraction. Genetic variation accounted for 22.9% overall AF SNP heritability. Addition of the AF genetic risk score to clinical risk factors improved risk model performance in classifying AF prevalence. Efforts are warranted to consider the role and mechanisms of genetic susceptibility of AF risk in heart failure patients.

Supplementary Information
Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. SNPs and weights used in the AF genetic risk score.

Figure S1. Venn diagram.

Funding
This work was supported by the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation; Renal Connection to microvascular disease and heart failure with preserved ejection fraction [CVON2014–11 RECONNECT] and a grant from the European Commission [FP7-242209-BIOSTAT-CHF]. C.P.N. and N.J.S. are funded by the British Heart Foundation.

Conflict of interest: C.R. is supported by a grant from Bayer AG to the Broad Institute focused on the development of therapeutics for cardiovascular disease. C.S.P.L. reports grants from National Medical Research Council of Singapore; grants and personal fees from Boston Scientific, Bayer, Roche Diagnostic, Vifor Pharma; grants from Medtronic; personal fees from AstraZeneca, Novartis, Amgen, Merck, Jensens Research & Development LLC, Menarini, Boehringer Ingelheim, Abbott Diagnostics, Corvia and Stealth Bio-Therapeutics, outside the submitted work. C.C.L. reports grants and other from AstraZeneca; grants from Amgen, Novartis; other from MSD and Servier; during the conduct of the study. L.L.N. reports grants from European Union FP7 programme, and John & Lucille Van Geest Foundation, during the conduct of the study. M.M. reports grants from European Community, during the conduct of the study; personal fees from Bayer, Novartis and Servier, outside the submitted work. S.A. reports grants and personal fees from Vifor Int; personal fees from Bayer, Boehringer Ingelheim, Novartis, Servier, Resplicardia, Impulse Dynamics; grants from Abbott Vascular; outside the submitted work. D.J.V.V. reports board membership fees/travel expenses from Johnson & Johnson, Novartis. E.J.B. reports grants from NHLBI (R01HL128914; 2R01 HL092577) and American Heart Association (18SFRN34110082). A.A.V. reports grants from European Commission, during the conduct of the study; personal fees from Amgen, Boehringer Ingelheim, AstraZeneca, Bayer, Cytokinetics, GSK, Myokardia, Novartis, Servier; grants and personal fees from Roche Diagnostics, outside the submitted work. The other authors have nothing to disclose.

References
1. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003;91:2D–8D.


